Literature DB >> 6349401

Treatment of acute nonspecific gastroenteritis of infants and young children with erythromycin.

R M Robins-Browne, H M Coovadia, M N Bodasing, M K Mackenjee.   

Abstract

A double-blind placebo-controlled trial of erythromycin ethylsuccinate was conducted in 65 infants and young children hospitalized with acute nonspecific gastroenteritis. Etiologic agents included rotaviruses (29%), Campylobacter jejuni (17%), "classical" enteropathogenic Escherichia coli (12%), enterotoxigenic E. coli (11%), Salmonella (9%), Shigella (2%), and Giardia lamblia (2%). No pathogens were obtained from 25 (38%) children. Treatment with erythromycin had no effect on the course of the illness in terms of the time required for hydration, stool frequency and temperature to return to normal, or for vomiting to be abolished. Children treated with erythromycin, however, experienced a marginally, but significantly (P less than 0.05), shorter period of abnormal stool consistency compared with control subjects. This effect was most pronounced in children from whom no enteropathogens were isolated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349401     DOI: 10.4269/ajtmh.1983.32.886

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Early treatment of Campylobacter jejuni enteritis.

Authors:  M D Williams; J B Schorling; L J Barrett; S M Dudley; I Orgel; W C Koch; D S Shields; S M Thorson; J A Lohr; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 2.  Antibiotic therapy for Shigella dysentery.

Authors:  Prince Rh Christopher; Kirubah V David; Sushil M John; Venkatesan Sankarapandian
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

3.  Erythromycin-resistant Campylobacter infections in Thailand.

Authors:  D N Taylor; M J Blaser; P Echeverria; C Pitarangsi; L Bodhidatta; W L Wang
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

4.  Burden of illness and factors associated with duration of illness in clinical campylobacteriosis.

Authors:  A E Deckert; R J Reid-Smith; S Tamblyn; L Morrell; P Seliske; F B Jamieson; R Irwin; C E Dewey; P Boerlin; S A McEwen
Journal:  Epidemiol Infect       Date:  2013-03-08       Impact factor: 4.434

5.  Adverse events in people taking macrolide antibiotics versus placebo for any indication.

Authors:  Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.